特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
232784

乾癬 : パイプライン製品の分析

Psoriasis - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 935 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
乾癬 : パイプライン製品の分析
出版日: 2020年03月31日
発行: Global Markets Direct
ページ情報: 英文 935 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

乾癬とは、皮膚に影響を及ぼす慢性的な自己免疫疾患を指し、細胞が乾燥して斑になった層の中で蓄積して炎症を起こします。症侯は、細胞の脱落を始め、皮膚の腫れ、かゆみ、焼けるような感覚などが生じます。関連のある危険因子として、遺伝、特定の薬剤の副作用、ストレス、感染症、環境的な状況等が挙げられます。局所あるいは全身投薬、光線治療で症状を抑えることができます。

当レポートでは、乾癬の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 乾癬 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

  • Number of Products under Development for Psoriasis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Psoriasis - Pipeline by 3SBio Inc, H1 2020
  • Psoriasis - Pipeline by AbbVie Inc, H1 2020
  • Psoriasis - Pipeline by Abcentra LLC, H1 2020
  • Psoriasis - Pipeline by AbClon Inc, H1 2020
  • Psoriasis - Pipeline by Abeome Corp, H1 2020
  • Psoriasis - Pipeline by AbGenomics International Inc, H1 2020
  • Psoriasis - Pipeline by Abivax SA, H1 2020
  • Psoriasis - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
  • Psoriasis - Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Psoriasis - Pipeline by Actinobac Biomed Inc, H1 2020
  • Psoriasis - Pipeline by ActoBio Therapeutics Inc, H1 2020
  • Psoriasis - Pipeline by ADiTx Therapeutics Inc, H1 2020
  • Psoriasis - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
  • Psoriasis - Pipeline by Affibody AB, H1 2020
  • Psoriasis - Pipeline by Affilogic SAS, H1 2020
  • Psoriasis - Pipeline by Agragen LLC, H1 2020
  • Psoriasis - Pipeline by Akeso Biopharma Inc, H1 2020
  • Psoriasis - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Psoriasis - Pipeline by Genentech Inc, H1 2020
  • Psoriasis - Pipeline by GeneScience Pharmaceuticals Co Ltd, H1 2020
  • Psoriasis - Pipeline by Genfit SA, H1 2020
  • Psoriasis - Dormant Projects, H1 2020
  • Psoriasis - Discontinued Products, H1 2020
  • Psoriasis - Discontinued Products, H1 2020 (Contd..1), H1 2020
  • Psoriasis - Discontinued Products, H1 2020 (Contd..2), H1 2020
  • Psoriasis - Discontinued Products, H1 2020 (Contd..3), H1 2020

List of Figures

  • Number of Products under Development for Psoriasis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12083IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H1 2020, provides an overview of the Psoriasis (Immunology) pipeline landscape.

Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 27, 39, 60, 3, 138, 39 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 4 molecules, respectively.

Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
    • Psoriasis - Overview
    • Psoriasis - Therapeutics Development
    • Psoriasis - Therapeutics Assessment
    • Psoriasis - Companies Involved in Therapeutics Development
    • Psoriasis - Drug Profiles
    • Psoriasis - Dormant Projects
    • Psoriasis - Discontinued Products
    • Psoriasis - Product Development Milestones
    • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.